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Stereotactic technique and the introduction of deep brain stimulation (DBS) can be consid-
ered two milestones in the ﬁeld of surgical neuromodulation. At present the role of DBS
in the treatment of clinically and epidemiologically relevant movement disorders is widely
accepted and DBS procedures are performed in many clinical centers worldwide. Here we
review the current state of the art of DBS treatment for the most common movement
disorders: Parkinson’s disease, essential tremor, and dystonia. In this review, we give a
brief description of the candidate patient selection criteria, the different anatomical targets
for each of these condition, and the expected outcomes as well as possible side effects.
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INTRODUCTION
Movement disorders encompass a number of neurological dis-
eases affecting the ability to control movement. Movement is in
command of several interacting brain structures, including the
motor cortex, the cerebellum, and the basal ganglia (BG). The BG
comprises a group of interconnected deep brain nuclei [caudate
and putamen (C–P), Globus pallidus (GP), substantia nigra (SN),
subthalamic nucleus (STN)] that, through their connections with
the thalamus and the cortex, primarily inﬂuence the involuntary
components of the movement and muscle tone. Disruption of this
complex circuitry within the BG causes the most frequent move-
ment disorders, such as Parkinson’s disease (PD), essential tremor
(ET), and dystonia (Alexander et al., 1990). The treatment of these
disorders with the deep brain stimulation (DBS) technique is the
topic of the present review,which describes the current clinical use
and approval of DBS indications.
Already in the 1950s, some early studies evaluated the possi-
ble therapeutic beneﬁts of chronic stimulation of the subcortical
structure in psychotic patients (Hariz et al., 2010). Nevertheless,
modernDBSwasﬁrst clinically used in the treatment of movement
disorders. Several reviews provide a comprehensive account of the
symptoms/syndromes thatmight be the target of this treatment, its
clinical efﬁcacy, aswell as its possible complications and side effects
(Skidmore et al., 2006;Wichmann and Delong, 2006; Collins et al.,
2010). The DBS surgical treatment of movement disorders has
its foundations in two seminal papers by the “Grenoble Group”
of Benabid et al. (1987) describing the combined (thalamotomy
and stimulation) stereotactic surgery of the ventral intermediate
(VIM) nucleus of the thalamus and, in 1993, DBS of the STN for
PD patients (Pollak et al., 1993). Modern DBS followed ablative
stereotaxy that was performed for most of the twentieth century
for medically refractory severe movement disorders, mostly PD
and ET,with selective destruction of parts of the GP or of the thal-
amus (Schwalb and Hamani, 2008). Although the procedure was
largely effective in relieving the symptoms, it was irreversible, and
in some cases side effects were actually encountered. As a result,
in the 1970s, following the advent of the highly effective levodopa
treatment for PD, ablative surgery was largely abandoned. How-
ever, after the initial enthusiasm for the medical treatment of PD,
it was apparent that long-term levodopa therapy had signiﬁcant
drug-induced complications (the so-called “long-term levodopa
syndrome”) mainly consisting in involuntary movements (dyski-
nesias) andmotor ﬂuctuations,which couldhave a severe disabling
effect in a signiﬁcant percentage of levodopa-treated PD patients.
In addition, among the classic symptomatologic triad of PD –
bradykinesia, rigidity, and resting tremor – this latter symptom
is always less responsive to levodopa treatment (Fishman, 2008).
Therefore, many clinical centers took advantage of the fact that
DBS technology is less invasive than stereotactic surgery, and is also
reversible and adjustable, more suitable for an increasing number
of medically treated PD patients with disabling dyskinesias/motor
ﬂuctuations and/or medically refractory tremor (Collins et al.,
2010).
The DBS technique uses continuous high-frequency stimu-
lation of speciﬁc brain regions through chronically implanted
electrodes, connected to a pulse generator, similar to a cardiac
pacemaker, that is telemetrically programmable. Electrodes are
implanted into the target brain area by using a stereotactic surgi-
cal procedure with electrophysiological recordings. Clinically, the
effects of DBS mimic those produced by lesioning the target struc-
ture (Schwalb and Hamani, 2008). However – at the cellular or
pathway level – the actions of high-frequency DBS that mediate its
clinical efﬁcacy are not fully understood. Indeed, recent evidence
suggests that DBS has more complex mechanisms of action than
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the pure functional inactivation of the target region. For instance,
high-frequency stimulation of the most used target structures for
DBS in PD and ET, i.e., the STN and the internal part of the GP
(GPi), not only produces both inhibitory and excitatory effects on
local neurons, but has also a modulatory inﬂuence on the afferent
inputs to the target nucleus and on the efferent outputs (McIn-
tyre et al., 2004). In any case, the ultimate effect of modulating
the network activity within the BG can be viewed as the takeover
on hyperactive elements or structures of the cortico-BG-thalamo-
cortical complex circuit (Gradinaru et al., 2009; Kopell et al., 2009;
McIntyre and Hahn, 2010).
PARKINSON’S DISEASE
Parkinson’s disease is the second most common neurodegenera-
tive disease. Its complex multifactorial etiology might comprise,
from recent genetic and epidemiological studies, genetic suscepti-
bility factors, and environmental risk factors. PD is a progressive
disease with age-dependent increasing prevalence (from1 to 3% in
the population aged over 65 years; Wirdefeldt et al., 2011). Loss of
SN pars compacta (SNc) dopaminergic neurons projecting to the
C–P is considered the neuropathologic hallmark of PD. The con-
sequent reduced dopaminergic input is considered the cause of the
motor manifestations of the disease (bradykinesia, rigidity, resting
tremor, and postural instability) and the reason for the remark-
able clinical success of dopamine replacement therapy. However,
it has become increasingly apparent that the neuropathological
changes of PD (mostly alpha-synuclein pathology) extend far
beyond the nigro-striatal system, affecting also the olfactory bulbs,
and the autonomic nervous system, many structures of the lower
brainstem, the limbic system, as well as the mesocortical and neo-
cortical regions. Most of the extra-nigral pathological alterations
are considered responsible of the non-motor symptoms of the dis-
ease, such as hyposmia, autonomic dysfunctions, sleep disorders,
depression, and cognitive impairments (Braak et al., 2003).
Nevertheless, with regard to DBS treatment in PD, the main
focus is on the progressive degeneration of the nigro-striatal
dopaminergic projections and the appearance of disabling side
effects, i.e., motor ﬂuctuations and dyskinesias, in a large percent-
age of PD patients on long-term dopaminergic therapy (Schrag
and Quinn, 2000). Because such complications are often poorly
managed by oral therapy, it is estimated that more than 10% of
PD patients could beneﬁt from DBS treatment. The selection of
candidate patients for DBS has strict inclusion/exclusion criteria.
The best candidates are PD patients with severe motor symp-
toms in the off-medication condition that continues to indicate
a substantial beneﬁt from levodopa therapy, despite the disabling
drug-induced motor complications. Main exclusion criteria are
the presence of symptoms suggesting an atypical parkinsonian
syndrome that usually does not respond to levodopa therapy,or the
presence of neuropsychiatric (depression) or cognitive alterations
(Bronstein et al., 2011).
There are four possible target sites for the placement of the
stimulating electrodes: although stimulation of the VIM thala-
mic nucleus has a clear effect on tremor, DBS of the STN, or GPi
has a broader inﬂuence on all parkinsonian symptoms and repre-
sents, nowadays, the treatment of choice in most PD patients. A
more recent, still experimental, target is the pedunculopontine
nucleus (PPN) that may be appropriate for patients with gait
freezing (Stefani et al., 2007; Wilcox et al., 2011). Because most
patients undergoing the DBS procedure have bilateral symptoms,
both right and left STN or GPi are usually implanted for maxi-
mal beneﬁt. Any parkinsonian symptom that can improve with
levodopa can also improve with DBS. Three recent randomized
controlled studies in patients with PD reported that STN DBS
plus best medical therapy was more effective than best medical
therapy alone in improving motor function and quality of life,
but was also associated with an increased risk of serious adverse
events (Deuschl et al., 2006; Weaver et al., 2009; Williams et al.,
2010). After neurostimulation, the clinical response is more stable
during the day, with signiﬁcant lessening of the “off” periods that
are so frequent and disabling in PD patients. Furthermore, DBS
reduces levodopa-induced dyskinesias. In the case of STN DBS,
this effect could be mostly ascribed to the reduction in medica-
tion dose, possible when the stimulation is active. GPi stimulation
patients experience a reduction in dyskinesias without any lev-
odopa dose reduction (Weaver et al., 2009; Follett et al., 2010).
In addition, reduction of dopaminergic therapy after STN DBS
may help in reducing some psychiatric symptoms, like visual hal-
lucinations and impulse control abnormalities, which are frequent
behavioral complications in the treatmentwith dopamine agonists
(Lulé et al., 2012).
Complications related to surgery are primarily intracerebral
hemorrhage (less than 2% in most centers) and infection (in
about 4% of the cases; Kleiner-Fisman et al., 2006). STN DBS can
worsen speech and gait in some patients, requiring an adjustment
of stimulation parameters. A recent study reported that depression
worsened with STN DBS but was improved with GPi DBS (Follett
et al., 2010). There are several reports that describe neuropsychi-
atric symptoms following STN DBS in PD patients. However, such
symptoms were generally transient and mild if managed appropri-
ately (Volkmann et al., 2010). With these possible complications
in mind, we can say that DBS offers important symptomatic ben-
eﬁts in cognitively intact PD patients with moderate disability
who still maintain a therapeutic response to levodopa. Medium-
and long-term studies have provided evidence that stimulation-
induced motor improvement was still evident at 5–8 years’ follow-
up (Fasano et al., 2010; Moro et al., 2010). However, DBS does
not modify the progression of the underlying PD pathology, so,
after years, patients can still develop disabling levodopa-resistant
symptoms, like gait disturbances and cognitive impairment.
ESSENTIAL TREMOR
Essential tremor is one of the most common movement disorders
with prevalence that varies depending on age, raising up to 5% in
the population over 60. The typical postural and action tremor is
most often located in the upper limbs; less frequently it affects the
head, the tongue, and the lower limbs. Even though the quality of
life is impaired by tremor in more than 70% of patients, only 10%
are medically treated. In addition, only 50% of treated patients
show a good response to therapy (Lyons et al., 2003). In the mid-
dle of the twentieth century the ventrolateral thalamus became the
main surgical target for parkinsonian and various other types of
tremor, including ET. After the introduction, in the early 60s, of
micro recording during stereotactic surgery, it became apparent
Frontiers in Integrative Neuroscience www.frontiersin.org January 2012 | Volume 6 | Article 2 | 2
Pizzolato and Mandat DBS for movement disorders
that small lesions of the VIM could suppress tremor. Afterward,
unilateral stereotactic VIM lesioning was a frequent procedure in
many clinical centers worldwide and resulted in a permanent sig-
niﬁcant contralateral improvement of the most common types
of tremor. However, the very satisfactory results in controlling ET
and other types of tremors (signiﬁcant reduction of limb tremor in
80–90% of patients with ET) obtained thanks to the thalamotomy,
were accompanied by a relatively high complication rate, especially
if the procedure was performed bilaterally. In fact, almost 30% of
patients who underwent the ablative procedure bilaterally expe-
rienced permanent speech and cognitive deﬁcits. Introduction of
DBSof the thalamicVIMnucleus in ET treatment helped to reduce
complication rate with remaining high efﬁcacy. Therefore, VIM
DBS is viewed as the target therapy for these patients with a debil-
itating ET. Although the exact etiology and pathophysiology of
ET is still unknown, it is believed that high-frequency stimulation
of the VIM nucleus may block the abnormal oscillatory activity
within the interconnected regions, including the cerebellum and
the motor cortex (Dostrovsky and Lozano, 2002).
The main exclusion criteria of DBS treatment for ET include
altered cognition and thepresenceof anuntreatedordisablingpsy-
chiatric illness. Patients with ET are considered good DBS candi-
date if theywere also refractory to an adequate trial of accepted oral
medications (Katz et al., 2011). The most frequent stimulation-
induced side effects are paresthesias, followed by dysarthria and
pain, symptoms that are reversible when the stimulation is turned
off. Furthermore, gait/balance may worsen following DBS for
medication refractory ET (Hwynn et al., 2011). The high initial
efﬁcacy of VIM DBS declines over time (Schuurman et al., 2008).
However, most patients experience a good response for several
years.
DYSTONIA
Dystonia is a movement disorder that presents with sustained,
uncontrolled, often painful muscle contractions causing repetitive
movements and abnormal postures. Depending on the localiza-
tion, dystonia is divided into focal (affecting a single body region),
segmental (two or more adjacent areas), or generalized (involving
the legs, or one leg and the trunk, plus at least one other area of the
body). Depending on etiology, dystonia might be primary (idio-
pathic) or secondary to a known structural lesion of the brain, like
perinatal hypoxia, infections, stroke, and trauma. Idiopathic dys-
tonia in adults is most commonly a focal/segmental disease, like
cervical dystonia (the most common form), blepharospasm, or
writer’s cramp, whereas in children and young adults the general-
ized inherited forms are more common. There are multiple forms
of inheritable dystonia, with the DYT-1 gene mutation, responsi-
ble for early-onset generalized dystonia, as the most frequent form
(Albanese et al., 2011). Medical therapy is very effective in a very
limited subset of dystonia patients (20–40%). In addition, doses of
drug(s) required for therapy often produce intolerable side effects.
Dystonia is still one of the most important indications for botu-
linum toxin (BT) therapy that selectively blocks the cholinergic
innervation of the muscles. BT can be used to treat focal dysto-
nias and also the most relevant target muscles in segmental and
generalized dystonias. Combinations of BT therapy with all other
treatment options, including DBS, are possible.
Patients with dystonia who might be evaluated for DBS treat-
ment should have symptoms that cause signiﬁcant disability,
despite maximally tolerated medical treatment. The factors that
inﬂuence the selection of patients with various types of dystonia
for treatment with DBS have been recently reviewed by Bronte-
Stewart et al. (2011). Patients candidate to surgery should undergo
DBS treatment before the onset of orthopedic deformities that
may impede functional beneﬁt even if dystonia is ameliorated by
DBS. The exact pathophysiological mechanisms of dystonia are
not completely understood and the best brain target for DBS in
dystonic patients has not been quite identiﬁed yet. However, a lot
of evidence indicates that the interplay between the BG and cere-
bellar circuits has a major role. In particular, the GPi has been
proven to show an abnormal ﬁring activity in dystonia, and GPi
is the usual target of DBS for such patients. On the other hand,
previous studies on STN stimulation in dystonia gave contrasting
results (Detante et al., 2004; Sun et al., 2007). In a 3-year follow-up
study, the beneﬁcial effects of bilateral GPi stimulation in young
patients with identiﬁed DYT-1 mutation reached 90% (Coubes
et al., 2000). Positive effects of DBS on dystonia scales, quality of
life, and pain reduction have been conﬁrmed in different studies
also in adults with primary generalized dystonia and in heteroge-
neous groups comprising patients with secondary or focal disease
(Vidailhet et al., 2005; Kupsch et al., 2006; Andrews et al., 2010).
Dynamic movements are the ﬁrst that respond to DBS, whereas
improvement of persistent dystonic posture could be observed
after months or years (Welter et al., 2010). Because improvement
may take months to occur, the evaluation of the efﬁcacy of DBS
treatment is more challenging than in patients with PD or ET.
Another difference with the DBS system in PD is that the optimal
frequency and amplitude stimulation settings needed for DBS in
many dystonia patients are higher than for GPi DBS in PD, and
much higher than for STN DBS in PD patients.
PERSPECTIVES ON EVOLUTION OF DEEP BRAIN
STIMULATION
Currently, the DBS technique uses electrodes of 1.3mm in diam-
eter integrating four contacts of 1.5mm length each, connected
to an internal pulse generator. Minimizing the hardware dimen-
sions remains one of the goals of DBS development, to allow the
implantation of the internal pulse generator in the scalp or within
the skull. Minimizing the size of the hardware would also allow
implanting multiple electrodes to multiple anatomical targets of
the brain more precisely and effectively. Further development of
DBS will probably depend on the use of multiple electrodes with
“closed-loop” systems that include macro recordings and stim-
ulation. The inﬂuence of local monitoring of neurotransmitter
activity might impact on the patterns of stimulation, particularly
with regard to the interactions between stimulation and medica-
tions. Moreover, since the introduction of the DBS technique the
lifespan of the battery has increased twice, but programming the
stimulation today is performed via telemetry that requires sev-
eral time consuming visits before the best therapeutic effect can
be reached. In the future, development of “closed-loop” DBS sys-
tems and neuroimaging modalities might allow the performance
of effective and safe programming through remote access, such as
the telephone or the Net (Andrews, 2010; Shah et al., 2010).
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The role of DBS for PD, ET, and dystonia is a well-established
treatment option, currently approved for use in the United States
(DBS for drug refractory primary dystonia received in 2003 the
FDA approval as humanitarian use device – HUD), Canada,
Europe, and Australia. As the indications for DBS broaden to
include other neurological and psychiatric conditions, the number
of DBS implants worldwide is expected to grow in the next years.
In 2009, treatment with DBS of obsessive compulsive disorder
(OCD) was approved by FDA as HUD and received the CE mark
approval. In 2010, the CE mark for DBS treatment of Epilepsy
refractory to medical treatment was also granted. On-going clini-
cal trials with DBS in the treatment of mood disorders, tremor
in multiple sclerosis, pain and cluster headache, hypertension,
minimally conscious state, obesity, memory impairment, aggres-
siveness, drug addiction, and other CNS disorders will increase
the number of indications for DBS in the future (Lyons, 2011).
However, the fact that FDA allowed DBS to be used in dysto-
nia or OCD under an humanitarian device exemption (HDE)
application, thereby without the need for a randomized clinical
trial of sufﬁcient size to demonstrate statistically signiﬁcant ben-
eﬁt without undue harm, has spurred impassioned debate on the
regulatory and ethical issues linked to the clinical use of DBS (Fins
et al., 2011). These issues likely will become even more urgent as
the number of indications for DBS treatment will increase.
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